



Republic of the Philippines  
Department of Health  
**CENTRAL OFFICE BIDS AND AWARDS COMMITTEE**

**COBAC RESOLUTION NO. 2021-055-A**  
15 April 2021

**RECOMMENDING APPROVAL OF THE AWARD OF CONTRACT FOR THE  
PROCUREMENT OF HEPATITIS B VIRAL LOAD REAGENTS RE-BID  
IB No. 2021-072-A**

**WHEREAS**, an Open Competitive Bidding for the Procurement of Hepatitis B Viral Load Reagents Re-bid was conducted in accordance with Republic Act (RA) 9184 and its 2016 Revised Implementing Rules and Regulations (IRR) through the General Appropriations Act of 2021 with a total Approved Budget for the Contract (ABC) of Eight Million Nine Hundred Twenty-Eight Thousand Philippine Pesos (PhP8,928,000.00):

Item No.	Particular	Qty.	Unit	Total ABC (PhP)
1	Hepatitis B Viral Load Reagents Re-bid	62	Set	8,928,000.00

**WHEREAS**, the COBAC Resolution No. 2021-055 "Declaration of Failure of Bidding for the Procurement of Hepatitis B Viral Load Reagents" was approved;

**WHEREAS**, on 04 February 2021, the Mandatory Review and Pre-procurement Conference was conducted at 11:30 A.M. at the COBAC Conference Room, Building 6, Department of Health (DOH) and through Cisco Webex, to determine the readiness of the procurement at hand;

**WHEREAS**, on 11 February 2021, the Invitation to Bid (IB) was posted in the PhilGEPS and DOH websites and in conspicuous places within the premises of the DOH for a continuous period of seven (7) calendar days;

**WHEREAS**, the Technical Working Group (TWG) was created through the issuance of Department Personnel Order COBAC No. 2021-109 dated 11 February 2021;

**WHEREAS**, on 18 February 2021, the Pre-bidding Conference took place as scheduled at 10:00 A.M. at the COBAC Conference Room, Building 6, DOH and through Cisco Webex, two (2) prospective bidders attended the cited conference, namely:

1. Macare Medicals Inc. (MMI); and,
2. Metro Drug Inc. (MDI);

**WHEREAS**, on 19 February 2021, the Minutes of Meeting of the Pre-bidding Conference was posted in the DOH website;

**WHEREAS**, on 22 February 2021, a letter was received through electronic mail (email) from MDI requesting clarification on the Technical Specifications of the posted Bidding Documents within the prescribed timeline;

**WHEREAS**, on 26 February 2021, the COBAC-C issued a memorandum to Disease Prevention and Control Bureau (DPCB) forwarding the letter of MDI for their perusal and appropriate action;

**WHEREAS**, on 01 March 2021, the COBAC-C issued a letter to MDI to acknowledge receipt of their letter;

**WHEREAS**, Bid Bulletin No. 1 dated 03 March 2021 was issued to announce the postponement of Submission and Opening of Bids until further notice which was previously set on 04 March 2021;

**WHEREAS**, on 04 March 2021, a follow up memorandum was issued to DPCB;

**WHEREAS**, on 08 March 2021, a memorandum was received from DPCB in response to the letter of MDI;

**WHEREAS**, a Bid Bulletin No. 2, dated 10 March 2021, was issued to announce the new schedule of the Submission and Opening of Bids, and to respond to the request for clarification of MDI;

**WHEREAS**, one (1) prospective bidder bought the bidding documents and submitted its bid proposal, namely, MDI JV with Interpharma Holding and Management Corp (MDI JV with IHMC);

**WHEREAS**, on 18 March 2021, the Submission and Opening of Bids took place as re-scheduled at 9:00 A.M. at the COBAC Conference Room, Building 6, DOH and through Cisco Webex;

**WHEREAS**, the first envelope, containing the Eligibility and Technical Documents, was opened and the presence, completeness and correctness of all the documents were verified by the COBAC-C in the presence of the prospective bidder's representative. Upon examination, MDI JV with IHMC was declared "ELIGIBLE";

**WHEREAS**, the second envelope, containing the Financial Proposal, was opened and the presence, completeness and correctness of the Financial Documents were verified by the COBAC-C. Upon examination, the lone eligible bidder was rated "PASSED" and subsequently its proposal was read out publicly and posted in the Abstract of Bids as read, to wit:

Name of Company					MDI JV with IHMC
Bid Security					Bid Securing Declaration
Amount					n/a
Validity					120 calendar days
Remarks					Eligible and Passed
Item no.	Item description	Qty	Unit	Total ABC (PhP)	Total Bid Price as Read (PhP)
1	Hepatitis B Viral Load Reagents Re-bid	62	Set	8,928,000.00	8,928,000.00

**WHEREAS**, the COBAC-C declared MDI JV with IHMC as the single bid as read subject to further arithmetical correction of the financial bid, if necessary;

**WHEREAS**, on 19 March 2021, the evaluation of the financial proposal of MDI JV with IHMC was undertaken by the designated TWG - Financial evaluator and subsequently submitted the Abstract of Bids as Calculated, to wit:

Item No. 1 – 62 sets of Hepatitis B Viral Load Reagents

Bidder's Rank	Name of Company	ABC (PhP)	Bid as Calculated Amount (PhP)	% Variance from ABC
Single Calculated Bid (SCB)	MDI JV with IHMC	8,928,000.00	8,928,000.00	0.00%

**WHEREAS**, on 22 March 2021, the Abstract of Bids as Calculated was presented to the COBAC-C during its 27<sup>th</sup> Regular Meeting. Upon review, the Committee decided to proceed with the Post-qualification of the SCB, particularly MDI JV with IHMC;

**WHEREAS**, on 23 March 2021, the COBAC-C issued a letter through e-mail to MDI JV with IHMC requesting for the submission of the Post-Qualification requirements within a non-extendible period of five (5) calendar days upon receipt of notification;

**WHEREAS**, on 24 March 2021, MDI JV with IHMC submitted its Post-Qualification requirements within the prescribed timeline;

**WHEREAS**, on 29 March 2021, the detailed evaluation of the eligibility, technical requirements and post-qualification documents of the SCB were undertaken by the designated TWG to verify, validate and ascertain the documents submitted by the SCB;

**WHEREAS**, on the same date, the TWG Legal, Technical and Financial found the bid of MDI JV with IHMC "Responsive" and subsequently submitted their reports;

**WHEREAS**, on the same date, the TWG report was presented to the COBAC-C during its 29<sup>th</sup> Regular Meeting. Upon review and deliberation, the Committee concurred with the recommendations of the TWG and declared MDI JV with IHMC, "Post-qualified";

**WHEREAS**, on 13 April 2021, the TWG submitted the Bid Evaluation and Post-Qualification Report (BEPQR) citing MDI JV with IHMC "Responsive" to all the requirements and conditions specified in the bidding documents;

**WHEREAS**, on 15 April 2021, the BEPQR was presented. The Committee reviewed and deliberated the TWG report as well as the documents submitted by the SCB for the item listed below and the following are the salient points of the deliberation:

Item No.	Description	Name of Bidder	Bidder's Rank	Total ABC (PhP)	Bid Price (PhP)	TWG		COBAC	
						Finding	Recommendation	Finding	Recommendation
1	Hepatitis B Viral Load Reagents	MDI JV with IHMC	SCB	8,928,000.00	8,928,000.00	The SCB passed the post qualification and found to have complied with the legal, technical and financial requirements.	Responsive	<ul style="list-style-type: none"> <li>• COBAC conforms with the recommendation of the TWG</li> <li>• MDI JV with IHMC is determined to be responsive and have complied to all the requirements and conditions as specified in the Philippine Bidding Documents and recommended for the award of contract.</li> </ul>	Single Calculated and Responsive Bid (SCRB)

**WHEREAS**, at the time of the signing of this resolution, there is no pending incident, no pending Request for Reconsideration, no pending Protest and the COBAC-C followed the requirements set forth in R.A. 9184;

**NOW THEREFORE**, in consideration of the above premises, the herein members of the COBAC-C **HEREBY RESOLVE** to recommend the award of contract to **Metro Drug Inc. JV with Interpharma Holdings and Management Corporation** determined as the Single Calculated and Responsive Bid with a Total Contract Price of Eight Million Nine Hundred Twenty-Eight Thousand Philippine Pesos (PhP8,928,000.00) inclusive of other taxes for the item listed below:

Item No.	Description	Qty.	Unit	Total Bid Price (PhP)
1	Hepatitis B Viral Load Reagents	62	Set	8,928,000.00

APR 26 2021

Signed this \_\_\_\_\_ day of \_\_\_\_\_ 2021 at the Department of Health, San Lazaro Compound, Sta. Cruz, Manila.

**CENTRAL OFFICE BIDS AND AWARDS COMMITTEE (COBAC) - C**

**DAVID P. MASIADO JR., ME, MM**  
Regular Member

(absent)  
**GLORIA J. BALBOA, MD, MHA, MPH, CEO VI, CESO III**  
Regular Member

**ERIC A. GUERRERO, MHA**  
Regular Member

**ANGELINA A. DEL MUNDO, MA, CESO III**  
Vice-Chairperson

**ROMEO A. ONG, MD**  
Assistant Secretary of Health  
Chairperson

By Authority of the Secretary of Health:

**BEVERLY LORRAINE C. HO, MD, MPH**  
Director IV  
Disease Prevention and Control Bureau

MAY 05 2021